Skip to main content
    C

    CervoMed Inc. (CRVO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.67
    -0.02 (-1.18%)

    Market Cap: $25.57M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    CervoMed Inc. (CRVO) Financials: Revenue, Profit and Cash Flow

    Updated Nov 6, 2026. Financial statements from company filings, amounts in US dollars.

    CervoMed reported revenue of $4.01M for the fiscal year ended Dec 31, 2025, down 58.9% from the year before. That year, net income was -$26.97M with a net margin of -673.1%, operating cash flow was -$23.45M and free cash flow was -$23.45M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$5.90M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$4.01M-58.9%100.0%-706.2%-673.1%
    Dec 2024$9.74M+36.3%100.0%-187.2%-167.3%
    Dec 2023$7.14MN/A100.0%-109.3%-30.4%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$4.01M$9.74M$7.14M$0$0$0$0$0$0$0
    Gross profit$4.01M$9.74M$7.14M$0$0$0$0$0$0$0
    Research and development$21.82M$18.80M$8.44M$1.34M$8.50M$9.43M$6.62M$5.75M$5.09M$7.25M
    Operating income-$28.29M-$18.23M-$7.81M-$3.48M-$24.68M-$15.97M-$11.55M-$18.96M-$11.35M-$18.37M
    Net income-$26.97M-$16.29M-$2.17M-$5.80M-$24.10M-$14.19M-$11.80M-$18.37M-$1.36M-$18.04M
    EBITDAN/AN/A-$2.39MN/A-$24.58M-$15.87M-$11.45M-$18.85M-$2.27M-$18.31M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$8.73K$322.57K$1.76M$1.92M$2.16M$1.94M$3.29M$2.35M$2.49M
    Gross profit$0$0$0$8.73K$322.57K$1.76M$1.92M$2.16M$1.94M$3.29M$2.35M$2.49M
    Operating income-$6.10M-$6.68M-$8.11M-$8.33M-$8.04M-$6.62M-$5.30M-$7.24M-$5.40M-$3.00M-$2.59M-$2.48M
    Net income-$5.90M-$6.57M-$7.96M-$8.09M-$7.73M-$6.26M-$4.89M-$6.71M-$4.75M-$2.32M-$2.51M-$2.36M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $8.24M were 36.0% of total assets of $22.88M, against total liabilities of $4.66M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$22.88M$43.08M$9.97M$4.16M$37.84M$27.73M$24.11M$18.20M$26.15M$17.48M
    Current assets$22.88M$43.08M$9.96M$4.16M$37.82M$18.78M$14.65M$8.91M$9.67M$1.60M
    Cash and equivalents$8.24M$9.00M$7.79M$4.09M$37.31M$18.52M$14.18M$7.99M$8.90M$1.55M
    Total liabilities$4.66M$3.88M$2.60M$13.16M$2.93M$2.92M$3.98M$2.59M$4.92M$8.30M
    Short-term debtN/AN/AN/A$12.41M$4.11M$113.47K$111.48KN/A$550.00K$1.88M
    Long-term debtN/AN/AN/AN/AN/AN/AN/AN/AN/A$550.00K
    Shareholder equity$18.22M$39.20M$7.38M-$33.29M$34.91M$24.81M$20.13M$15.61M$21.23M$9.18M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$21.33M$25.99M$15.11M$23.40M$30.61M$38.08M$38.58M$43.08M$48.88M$53.19M$8.00M$9.97M
    Total liabilities$3.97M$3.03M$4.50M$5.18M$4.60M$4.64M$3.94M$3.88M$3.25M$3.21M$2.66M$2.60M
    Cash and equivalents$6.06M$22.46M$7.94M$8.24M$9.44M$8.32M$10.50M$9.00M$7.74M$10.01M$6.37M$7.79M
    Shareholder equity$17.36M$22.96M$10.62M$18.22M$26.01M$33.44M$34.63M$39.20M$45.64M$49.98M$5.34M$7.38M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$23.45M-$16.53M-$7.45M-$2.57M-$14.50M-$13.55M-$9.86M-$10.77M-$12.33M-$10.77M
    Capital expenditures$0$3$3$1$0$0$0$0$447.82K$2.33K
    Free cash flow-$23.45M-$16.53M-$7.45M-$2.57M-$14.50M-$13.55M-$9.86M-$10.77M-$12.78M-$10.77M
    Share repurchasesN/AN/A$1.55M$0N/AN/AN/AN/AN/AN/A
    Investing cash flow$18.10M-$28.66M$0$0$4.00K$0$0$0-$447.82K$8.50M
    Financing cash flow$4.59M$46.40M$11.15M$0$33.30M$17.89M$16.04M$9.87M$20.12M$1.83M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$5.07M-$6.92M-$8.02M-$6.58M-$6.47M-$6.51M-$3.89M-$8.05M-$4.85M-$2.20M-$1.42M-$2.54M
    Capital expendituresN/AN/A$0$0$0$5$0$0$0$5$0$4
    Free cash flowN/AN/A-$8.02M-$6.58M-$6.47M-$6.51M-$3.89M-$8.05M-$4.85M-$2.20M-$1.42M-$2.54M
    Last 12 quarters

    Frequently Asked Questions About CRVO

    What is CervoMed's annual revenue?

    CervoMed reported revenue of $4.01M for the fiscal year ended Dec 31, 2025.

    How fast is CervoMed's revenue growing?

    Revenue was down 58.9% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is CervoMed profitable?

    No. CervoMed reported net income of -$26.97M for the fiscal year ended Dec 31, 2025, with a net margin of -673.1%.

    How much free cash flow does CRVO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$23.45M minus capital expenditures of $0 produced free cash flow of -$23.45M.

    How much debt does CervoMed have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $8.24M.